Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01068587 | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy | PHASE1 | COMPLETED | 31 | — | — | Jan 21, 2010 | Feb 13, 2015 | Aug 4, 2023 | 4 | Canada |
After completion of Phase I portion of the study
Assessed from the time of first dose. Results will be analyzed at time of final analysis
After completion of phase I
| Arm | Type | Description |
|---|---|---|
| Erlotinib | ACTIVE_COMPARATOR | - |
| Foretinib plus Erlotinib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MET/VEGFR2 inhibitor Foretinib | DRUG | PhaseI and Phase II Arm A: Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| erlotinib hydrochloride | DRUG | erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| laboratory biomarker analysis | OTHER | Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting all of the following criteria: * Locally advanced or metastatic disease * Failed 1-2 prior chemotherapy regimen * Must be eligible to receive erlotinib therapy (i.e., patients ...